HK Stock MarketDetailed Quotes

06622 ZHAOKE OPHTH-B

Watchlist
  • 1.580
  • +0.010+0.64%
Market Closed Mar 28 16:08 CST
862.90MMarket Cap-2030P/E (TTM)

About ZHAOKE OPHTH-B Company

Zhaoke Ophthalmology Co., Ltd. is an ophthalmology pharmaceutical company dedicated to the research, development and commercialization of ophthalmic treatments to meet the huge medical demand gap in China. With deep expertise in the field, we have established a comprehensive ophthalmic drug pipeline with 25 drug candidates through independent development or licensing, covering most major ophthalmic indications affecting the anterior and posterior ocular sections. To prepare for the upcoming product launch, we have also set up an advanced eye medicine manufacturing facility and are in the process of forming an experienced marketing team. Our goal is to become a leader in the Chinese and neighboring ASEAN markets. We are led by an international management team with decades of industry experience and track record in R&D, clinical operations, manufacturing, regulatory communications, business development, and commercialization of ophthalmic therapies. We have established an ophthalmic drug pipeline composed of 13 innovative drugs and 12 generic drugs (classified according to the National Drug Administration's “Administrative Measures on Drug Registration”). Eight drug candidates in our innovative pipeline have the potential to become leading products in the Chinese market if approved. Our generic drug pipeline includes six potential first-generation drugs in China, which we believe will bring us immediate cash flow and a significant first-mover advantage in commercial-scale manufacturing and marketing. According to insightful data, we have one of the most comprehensive ophthalmic drug pipelines in China. In designing our pipeline, we initially focused our strategy on China's top five ophthalmic indications (in terms of market potential), including dry eye, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. Through this product pipeline strategy, we strive to provide an indispensable one-stop solution. We have developed in-house capabilities in key areas of ophthalmic drug development. Our dedicated in-house R&D, clinical and regulatory capabilities enable us to simultaneously advance multiple innovative and generic drug candidates through pre-clinical and clinical stages. We have a strong track record in business development and have been approved by international partners to introduce a variety of drug candidates with high growth potential and for key indications. To differentiate ourselves from our Chinese competitors, we have set up a commercial-scale advanced production facility designed and built according to Chinese, American and EU cGMP standards to produce ophthalmic drugs. We are also in the process of forming an experienced commercial team with extensive experience covering various national sales channels in China and in dealing with ophthalmologists. We believe that these sophisticated capabilities will help us bring innovative, comprehensive eye treatments to the market and become the partner of choice for multinational pharmaceutical companies.

Company Profile

Symbol06622
Company NameZHAOKE OPHTH-B
ISINKYG989M51017
Listing Date04/29/2021
Issue Price16.80
Shares Offered123.57M share
Founded01/20/2017
RegistrationCayman Islands
ChairmanXiaoyi Li
SecretaryShuxin Qiu
Audit InstitutionKPMG
Company CategoryOther
Registered OfficeWalkers Corporate Limited 190 Elgin Avenue George Town Grand Cayman KY1-9008 Cayman Islands
Head Office and Principal Place of BusinessRoom 716, 7th Floor, Block 12W, Phase 3, Hong Kong Science Park, Shatin, Hong Kong
Fiscal Year Ends12-31
Employees313
MarketHong Kong motherboard
Phone(020)39062828;(852)23145100
Emailinfo@zkoph.com
Business Zhaoke Ophthalmology Co., Ltd. is a Chinese investment holding company mainly engaged in the development, manufacture and marketing of ophthalmic drugs. The company's products include innovative drugs and generic drugs. The company's products are mainly used in five ophthalmic indications, including dry eye (DED), wet age-related macular degeneration (WAMD), diabetic macular edema (DME), myopia, and glaucoma.

Company Executives

  • Name
  • Position
  • Salary
  • Xiaoyi Li
  • Nomination Committee Chairman,Executive Committee Chairman,Executive Director,CEO,Authorized Representative,Chairman of the Board
  • --
  • Xiangrong Dai
  • Executive Director,Executive Committee Member
  • --
  • Yeni Li
  • Non-Executive Director
  • --
  • Tiantian Zhang
  • Non-Executive Director,Remuneration Committee Member,Audit Committee Member
  • --
  • Yu Chen
  • Non-Executive Director
  • --
  • Xianrong Huang
  • Independent Non-Executive Director,Nomination Committee Member,Audit Committee Chairman,Remuneration Committee Member
  • --
  • Huaijing Liu
  • Independent Non-Executive Director,Audit Committee Member
  • --
  • Yulin Lu
  • Nomination Committee Member,Remuneration Committee Chairman,Independent Non-Executive Director
  • --
  • Liekui Liu
  • Chief Scientific Officer,President
  • --
  • Guohui Zhang
  • Deputy GM
  • --
  • Su Jiang
  • Director of Clinical Operations
  • --
  • Jian Ma
  • Senior Quality Control Manager
  • --
  • Xinyan Feng
  • CFO
  • --
  • Mauro Bove
  • Director of Business Development
  • --
  • Jiang Feng
  • Director of Marketing and Marketing
  • --
  • Shuxin Qiu
  • Finance Director,Company Secretary,Authorized Representative
  • --
  • Liu Liu
  • Head of Regulatory Affairs
  • --
  • Yixuan Jin
  • Deputy Director of Medicine
  • --
  • Samir Chandrakant Patel
  • Strategy Adviser
  • --
  • Lei Yang
  • General Counsel
  • --
  • Jianming Cai
  • Chief Medical Officer
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg